As of Feb 21
| +0.76 / +2.33%|
The 14 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 31.50, with a high estimate of 45.00 and a low estimate of 18.00. The median estimate represents a -5.43% decrease from the last price of 33.31.
The current consensus among 16 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.